ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$1039.78
1.66 (0.16%)
▲
5d:
+22.14%
30d:
+12.46%
90d:
+27.39%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 22, 2026
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ARGX is 14.8% above its trading range ($905.68). Market expects -0.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ARGX is 14.8% above its trading range ($905.68). Market expects -0.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1908.23
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1184.86
12.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $1039.78, which is considered extended relative to its 30-day fair value range of $843.23 to $905.68. The stock's valuation (Forward PE: 26.5) is in line with its historical norms (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This pessimistic expectation contrasts with the company's recent 95.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is in a uptrend. The price is approaching resistance at $1058.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ARGX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1172.78 (+12.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARGX is in a uptrend. The price is approaching resistance at $1058.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ARGX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1172.78 (+12.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$843.23 -
$905.68
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
16.7%
All Signals
- BEARISH: Price significantly overextended (+14.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($1172.78)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$843.23 -
$905.68
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$837.42
Resistance Level
$1058.69
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.53
Wall Street Target
$1172.78
(+12.8%)
Revenue Growth (YoY)
59.3%
Earnings Growth (YoY)
95.2%
Profit Margin
32.3%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
26.5 vs 27.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$1030.42
(-1%)
2-Year Target
$1021.15
(-2%)
3-Year Target
$1011.96
(-3%)
3-Yr Target (if PE normalizes)
(PE: 27→27)
$1041.42
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.5, Growth: 35.0%)
$2556.41
(+146%)
Base:
(SPY PE: 20.1, Growth: 35.0%)
$1934.10
(+86%)
Bear:
(PE: 17.1, Growth: 35.0%)
$1643.99
(+58%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Trailing PE: 39.49 | Current EPS (TTM): $26.29
Bull Case
$1702.53
(+64%)
Analyst growth 49.1%, PE expands to 43.4
Base Case
$1547.75
(+49%)
Market implied 49.1%, PE stable at 39.5
Bear Case
$705.92
(-32%)
Severe decline -20.0%, PE contracts to 33.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.5 to 27.3
Stabilization Target:
$1070.06
(+2.9%)
PE Expansion Potential:
+2.9%
Share & Embed Analysis
Last updated: August 24, 2026 4:36 AM ET
Data refreshes hourly during market hours. Next update: 5:36 AM
Data refreshes hourly during market hours. Next update: 5:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
